Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Advanced Rare Tumors
NCT06638931Phase 2Active, not recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in rare tumors, sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2024; status: active, not recruiting.
02
Drugs
03
Conditions
rare tumors
Beyond the preview
Go deeper on NCT06638931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638931.